PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-91

Hi All,

I was doing my monthly observations on Pharmaust V The Rest of the World in relation to Lymphoma B treatment.

Remembering Global Vet Oncology drug sales were 2020 USD $60 million and expected to be USD $86 million by 2026.

Which Companies are at the forefront.

1. Elanco with Aratana. Intravenous

2. Zoetis with Palladia. USD $6 per tablet

3. Nippon Zenyaku with a CD 20 antibody on trial Phase 2b.

4. Vet DC with Tanovea. ( ? Side effects)

5. Advavet with Doxorubicin ( Chemo drug ? Side effects )

That leaves us with one big Pharma Boehringer sitting by itself with a discontinued Lymphoma B drug that didn't complete a Phase 3 trial and a small Company called Rhizen Pharmaceutical that are specialising in T cell Lymphoma.

Of course on the PAA payroll is Dr Kim Agnew who was head of R & D Pacific Region Boehringer ( though it was called Merial ) back then.

RA has let it out we have a new partner.

Odds are shortening ?

Come May 2022 , I anticipate a big smile on our faces.

Everyone on this forum knows the Science is excellent.